en · de · es · fr · pt
glossary-desk.peptides6823.com › Wiki › Chemical Identity And Research Background — Explained

Chemical Identity And Research Background — Explained

By Editorial Desk · published 2026-04-21 · last reviewed 2026-05-25 · Wiki

A practical reference on Semax: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Handling, Storage, and Analytical Methods

Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.

Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SSeven-residue peptide
Molecular mass813.9 DaMonoisotopic value
AppearanceWhite to off-white powderLyophilized form
SolubilityFreely soluble in waterAlso soluble in saline and polar solvents
Storage (dry)-20 °C or lowerDesiccated, protected from light

Background and Development

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Related pages on this site

Semax 的储存、稳定性与分析

溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集,其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸,因此氧化风险相对突出。工作液一般主张现配现用,或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率,而关于最佳条件的公开数据并不统一。

常规纯度与身份确认依赖反相高效液相色谱,并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成,肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同,因此各实验室报告的纯度数值不宜直接横向比较。

Reference notes

== Biography == Sakel was born to a Jewish family on June 6, 1900, in Nadvirna (Nadwórna), in the former Austria-Hungary Empire (now Ukraine), which was part of Poland between the world wars. Sakel studied Medicine at the University of Vienna from 1919 to 1925, specializing in neurology and neuropsychiatry. From 1927 until 1933 Sakel worked in hospitals in Berlin. In 1933 he became a researcher for the University of Vienna's Neuropsychiatric Clinic. In 1936, after receiving an invitation from Frederick Parsons, a commissioner of mental hygiene, he chose to emigrate from Austria to the United States of America. In the USA, he became an attending physician and researcher at the Harlem Valley State Hospital. Dr. Sakel was the developer of insulin shock therapy from 1927 while a young doctor in Vienna, starting to practice it in 1933. It would become used widely for individuals with schizophrenia and other mental patients. He noted that insulin-induced coma and convulsions, due to the low level of glucose attained in the blood (hypoglycemic crisis), had a short-term appearance of changing the mental state of drug addicts and psychotics, sometimes dramatically. He reported that as many as 88% of his patients improved with insulin shock therapy, but most other people reported more mixed results and it was shown eventually that patient selection had been biased and that it didn't really have any specific benefits and had many risks, adverse effects and fatalities. However, his method was used for many years in mental institutions worldwide.

In the 15th century, Cossack society was described as a federation of independent communities, which often formed local cavalry units and were entirely independent from neighboring states such as Poland, the Grand Duchy of Moscow, and the Crimean Khanate. There are confusing historical reports, according to Mykhailo Hrushevsky, that "the first mention of Cossacks dates back to the 14th century", although that seems indicative of people who were either Turkic or of undefined origin. Hrushevsky states that a deeper intuitive study of the evolution of the Cossacks indicates they may have descended from the long-forgotten Antes, or from groups from the Berlad territory of the Brodnici in present-day Romania, then a part of the Grand Duchy of Halych. There, the Cossacks may have served as self-defence formations, organized to defend against raids conducted by aggressive far-ranging tribes. The first international mention of Cossacks was in 1492, when Crimean Khan Meñli I Giray complained accusingly to Grand Duke of Lithuania Alexander Jagiellon that the Grand Duke's Cossack subjects from Kiev and Cherkasy had pillaged a Crimean Tatar ship. The duke ordered his "Ukrainian" (meaning borderland) officials to investigate, execute the guilty, and give their belongings to the Khan. Sometime in the 16th century, there appeared an old Ukrainian Ballad of Cossack Holota, about a Cossack near Kiliya. In the 16th century Cossack societies evolved into two independent territorial organizations, as well as other smaller, still-detached groups:

The degree to which the virus is infectious during the incubation period is uncertain, but research has indicated that the pharynx reaches peak viral load approximately four days after infection or in the first week of symptoms and declines thereafter. The duration of SARS-CoV-2 RNA shedding is generally between 3 and 46 days after symptom onset. A study by a team of researchers from the University of North Carolina found that the nasal cavity is seemingly the dominant initial site of infection, with subsequent aspiration-mediated virus-seeding into the lungs in SARS‑CoV‑2 pathogenesis. They found that there was an infection gradient from high in proximal towards low in distal pulmonary epithelial cultures, with a focal infection in ciliated cells and type 2 pneumocytes in the airway and alveolar regions respectively. Studies have identified a range of animals—such as cats, ferrets, hamsters, non-human primates, minks, tree shrews, raccoon dogs, fruit bats, and rabbits—that are susceptible and permissive to SARS-CoV-2 infection. Some institutions have advised that those infected with SARS‑CoV‑2 restrict their contact with animals.

== Small molecule drug candidates == The key amino acids of the BSCI peptides required for activity have been identified, and the tripeptide AcNH-Trp-Val-Gln-OH was shown to itself be a BSCI in the low micromolar range. Based on this structure a number of peptide mimetics were designed, including a range of 3-acylaminoglutarimides, with low nanomolar BSCI potencies. The search for increased stability and potency led to the development of 3-acylaminolactams, with picomolar potencies in vitro and high anti-inflammatory activity in vivo. A small molecule member of this class of BSCIs called FX125L, under development by Funxional Therapeutics, has recently completed phase 2 clinical trials.

Sources: en.wikipedia.org

Reference notes

Lipidomics is the large-scale study of pathways and networks of cellular lipids in biological systems. The word "lipidome" is used to describe the complete lipid profile within a cell, tissue, organism, or ecosystem and is a subset of the "metabolome" which also includes other major classes of biological molecules (such as amino acids, sugars, glycolysis & TCA intermediates, and nucleic acids). Lipidomics is a relatively recent research field that has been driven by rapid advances in technologies such as mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, dual polarisation interferometry and computational methods, coupled with the recognition of the role of lipids in many metabolic diseases such as obesity, atherosclerosis, stroke, hypertension and diabetes. This rapidly expanding field complements the huge progress made in genomics and proteomics, all of which constitute the family of systems biology. Lipidomics research involves the identification and quantification of the thousands of cellular lipid molecular species and their interactions with other lipids, proteins, and other metabolites. Investigators in lipidomics examine the structures, functions, interactions, and dynamics of cellular lipids and the changes that occur during perturbation of the system. Han and Gross first defined the field of lipidomics through integrating the specific chemical properties inherent in lipid molecular species with a comprehensive mass spectrometric approach.

== Function == Class I MHC molecules bind peptides generated mainly from the degradation of cytosolic proteins by the proteasome. The MHC I: peptide complex is then inserted via the endoplasmic reticulum into the external plasma membrane of the cell. The epitope peptide is bound on extracellular parts of the class I MHC molecule. Thus, the function of the class I MHC is to display intracellular proteins to cytotoxic T cells (CTLs). However, class I MHC can also present peptides generated from exogenous proteins, in a process known as cross-presentation. A normal cell will display peptides from normal cellular protein turnover on its class I MHC, and CTLs will not be activated in response to them due to central and peripheral tolerance mechanisms. When a cell expresses foreign proteins, such as after viral infection, a fraction of the class I MHC will display these peptides on the cell surface. Consequently, CTLs specific for the MHC:peptide complex will recognize and kill presenting cells. Alternatively, class I MHC itself can serve as an inhibitory ligand for natural killer cells (NKs). Reduction in the normal levels of surface class I MHC, a mechanism employed by some viruses and certain tumors to evade CTL responses, activates NK cell killing.

=== Approved drugs === Emoxypine (ethylmethylhydroxypyridine; Mexidol) – antioxidant and unknown mechanism of action [135] Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT1A receptor partial agonist [136] Tianeptine (Coaxil; Stablon; Tatinol) – weak atypical μ-opioid receptor agonist and other actions [137]

Identify viral infection of a cell (viral protein expression). Determine an individual's susceptibility to cancer (oncogene expression). Find if a bacterium is resistant to penicillin (beta-lactamase expression). Gene expression profiling evaluates a panel of genes to help understand the fundamental mechanism of a cell. This is increasingly used in cancer therapy to target specific chemotherapy. (See RNA-Seq and DNA microarray for details.) Similarly, the analysis of the location of protein expression is a powerful tool, and this can be done on an organismal or cellular scale. Investigation of localization is particularly important for the study of development in multicellular organisms and as an indicator of protein function in single cells. Ideally, measurement of expression is done by detecting the final gene product (for many genes, this is the protein); however, it is often easier to detect one of the precursors, typically mRNA and to infer gene-expression levels from these measurements.

=== Mechanical analysis of biomolecular condensates === To identify liquid-liquid phase separation and formation of condensate liquid droplets, one needs to demonstrate the liquid behaviors (viscoelasticity) of the condensates. Furthermore, mechanical processes are key to condensate related diseases, as pathological changes to condensates can lead to their solidification. Rheological methods are commonly used to demonstrate the liquid behavior of biomolecular condensates. These include active microrheological characterization by means of optical tweezers and scanning probe microscopy.

Sources: en.wikipedia.org

Frequently asked questions

What is Semax chemically?

It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.

Why was the Pro-Gly-Pro tail added?

The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.

How strong is the clinical evidence?

Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.

How should semax powder be stored?

Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.

Network